Literature DB >> 2322929

Antitumor potential of low-dose chemotherapy manifested in combination with immunotherapy of Viva-Natural, a dietary seaweed extract, on Lewis lung carcinoma.

E Furusawa1, S Furusawa.   

Abstract

Beneficial antitumor effects of low-dose chemotherapy (Adriamycin, BCNU, cisplatin, 5-fluorouracil, methotrexate, 6-thioguanine or vincristine) combined with an immunotherapy with a partially purified polysaccharide of Viva-Natural, an edible seaweed extract, have been demonstrated against intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Adriamycin, cisplatin, 5-fluorouracil and vincristine at low doses, that were not effective when given alone, manifested antitumor activity when combined with the polysaccharide fraction of Viva-Natural. Other three drugs (BCNU, methotrexate and 6-thioguanine) at the noneffective low doses exhibited no further antitumor activity when combined with Viva-Natural. Cytotoxic activation of peritoneal macrophages in mice has been induced by single administration of the polysaccharide fraction of Viva-Natural, but the combined regimen of low dose drugs plus viva-Natural was no more effective than Viva-Natural alone. Therefore, the mechanism of action of the beneficial combination is not clear yet.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322929     DOI: 10.1016/0304-3835(90)90181-v

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Anticancer drugs from marine flora: an overview.

Authors:  N Sithranga Boopathy; K Kathiresan
Journal:  J Oncol       Date:  2011-02-27       Impact factor: 4.375

Review 2.  Medicinal Plants and Other Living Organisms with Antitumor Potential against Lung Cancer.

Authors:  Luara de Sousa Monteiro; Katherine Xavier Bastos; José Maria Barbosa-Filho; Petrônio Filgueiras de Athayde-Filho; Margareth de Fátima Formiga Melo Diniz; Marianna Vieira Sobral
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-24       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.